Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice

Toxicology and Applied Pharmacology

Volumn 267, Issue 3, 2013, Pages 256-265

  Niu, Xiaofeng ^a   Fan, Ting ^a   Li, Weifeng ^a   Huang, Huimin ^a   Zhang, Yanmin ^a   Xing, Wei ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Acetic acid induced colitis; Nuclear factor (NF) B; Sanguinarine; Ulcerative colitis

Indexed keywords

ACETIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; SALAZOSULFAPYRIDINE; SANGUINARINE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; COLON INJURY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; HISTOPATHOLOGY; MALE; MORTALITY; MOUSE; NONHUMAN; TREATMENT DURATION; ULCERATIVE COLITIS; WEIGHT REDUCTION;

ACETIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPHENANTHRIDINES; COLITIS, ULCERATIVE; ISOQUINOLINES; MALE; MICE;

ANIMALIA; MUS;

EID: 84873745626     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.01.009     Document Type: Article

References (68)

1. Akgun E., Caliskan C., Celik H.A., Ozutemiz A.O., Tuncyurek M., Aydin H.H. Effects of N-acetylcysteine treatment on oxidative stress in acetic acid-induced experimental colitis in rats. J. Int. Med. Res. 2005, 33:196-206.
2. Atreya I., Atreya R., Neurath M.F. NF-κB in inflammatory bowel disease. J. Int. Med. 2008, 263:591-596.
3. Autschbach F., Braunstein J., Helmke B., et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Pathol. 1998, 153:121-130.
4. Baeuerle P., Henkel T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 1994, 12:141-153.
5. Baker S., Campbell L. Enterocyte injury by oxygen-dependent processes. Gastroenterology 1991, 101:716-720.
6. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
7. Beffa D.C., Fischman A.J., Fagan S.P., Hamrahi V.F., Paul K.W., Kaneki M., Yu Y.M., Tompkins R.G., Carter E.A. Simvastatin treatment improves survival in a murine model of burn sepsis: role of interleukin 6. Burns 2011, 37:222-226.
8. Benamar K., Geller E.B., Adler M.W. Effect of a μ-opioid receptor-selective antagonist on interleukin-6 fever. Life Sci. 2002, 70:2139-2145.
9. Blackwell T.S., Christman J.W. The role of nuclear factor-κB in cytokine gene regulation. Am. J. Respir. Cell Mol. Biol. 1997, 17:3-9.
10. Buell M., Berin C. Neutrophil-independence of colonic injury. Comparison of results from three models of experimental colitis in the rat. Dig. Dis. Sci. 1994, 39:2575-2588.
11. Buraczynska M., Jozwiak L., Ksiazek P., Borowicz E., Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl. Res. 2007, 150:101-105.
12. Castro G.A. Myeloperoxidase and intestinal inflammation. Gastroenterology 1985, 88:1294-1295.
13. Cetinkaya A., Bulbuloglu E., Kurutas E.B., Ciralik H., Kantarceken B., Buyukbese M.A. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J. Exp. Med. 2005, 206:131-139.
14. Chaturvedi M.M., Kumar A., Darnay B.G., Chainy G.B., Agarwal S., Aggarwal B.B. Sanguinarine (pseudo chelerythrine) is a potent inhibitor of NF-kappa B activation, I kappa-phosphorylation, and degradation. J. Biol. Chem. 1997, 272:30129-30134.
15. Choudhary S., Keshavarzian A., Yong M., Wade M., Bocckino S., Day B.J., Banan A. Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats. Dig. Dis. Sci. 2001, 46:2222-2230.
16. Deventer S.J.H. Tumor necrosis factor and Crohn's disease. Gut 1997, 40:443-448.
17. Elson C.O., Sartor R.B., Tennyson G.S., Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109:1344-1367.
18. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
19. Francos V.H., Brusick D.J., Johnson E.M., Maibach H.I., Munro I., Squire R.A., Weil C.S. Safety of sauguinaria extract as used in commercial tooth- paste and oral rinse products. J. Can. Dent. Assoc. 1990, 56:41-47.
20. Godowski K.C., Wolff E.D., Thompson D.M., Housley C.J., Polson A.M., Dunn R.L., Duke S.P., Stoller N.H., Southard G.L. Whole mouth microbiota effects following subgingival delivery of sanguinarum. J. Periodontol. 1995, 66:870-877.
21. Gonzalez-Lama Y., Fernandez-Blanco I., Lopez-SanRoman A., Taxonera C., Casis B., Tabernero S., et al. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008, 55:1609-1614.
22. Grisham M.B. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994, 344:859-861.
23. Guo X., Wang W.P., Ko J.K., Cho C.H. Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats. Gastroenterology 1999, 117:884-892.
24. Holma R., Salmenpera P., Riutta A., Virtanen I., Korpela R., Vapaatalo H. Acute effects of the Cys-leukotriene-1 receptor antagonist, monteleukast, on experimental colitis in rats. Eur. J. Pharmacol. 2001, 429(1-3):309-318.
25. Hyams J.S., Lerer T., Griffiths A., Pfefferkorn M., Kugathasan S., Evans J., et al. Longterm outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm. Bowel Dis. 2009, 15:816-822.
26. Ishida H. Clinical implication of IL-10 in patients with immune and inflammatory diseases. Rinsho Byori 1994, 42:843-852.
27. Ito H., Takazoe M., Fukuda Y., Hibi T., Kusugami K., Andoh A., Matsumoto T., Yamamura T., Azuma J., Nishimoto N., Yoshizaki K., Shimoyama T., Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 receptormonoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126:989-996.
28. Kawamoto M., Matsui E., Kaneko H., Fukao T., Teramoto T., Kasahara K., Kondo N. IL-10 plays an important role as an immune-modulator in the pathogenesis of atopic diseases. Mol. Med. Rep. 2008, 1:837-842.
29. Kitahora T., Suzuki K., Asakura H., Yoshida T., Suematsu M., Watanabe M., Aiso S., Tsuchiya M. Active oxygen species generated by monocytes and polymorphonuclear cells in patients in Crohn's disease. Dig. Dis. Sci. 1998, 33:951-955.
30. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87:1344-1350.
31. Kruidenier L., Verspaget H.W. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous?. Aliment. Pharmacol. Ther. 2002, 16:1997-2015.
32. Kruidenier L., Kuiper I., Lamers C., Verspaget H.W. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J. Pathol. 2003, 201:28-36.
33. Kucharzik T., Stoll R., Lugering N., Domschke W. Circulating antiinflammatory Mcytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin. Exp. Immunol. 1995, 100:452-456.
34. Larrick J.W., Wright S.C. Cytotoxic mechanism of tumor necrosis factor-α. FASEB J. 1990, 4:3215-3223.
35. Luo J.Y., Cao J.C., Jiang X.L., Cui H.F. Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice. Biomed. Pharmacother. 2010, 64:441-445.
36. MacPherson B., Pfeiffer C. Experimental production of diffuse colitis in rats. Digestion 1978, 17:135-150.
37. Malek R., Borowicz K.K., Jargiełło M., Czuczwar S.J. Role of NF-κB in the central nervous system. Pharmacol. Rep. 2007, 59:25-33.
38. Martin A.R., Villegas I., Sanchez-Hidalgo M., Alarcón de la Lastra C. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 2006, 147:873-885.
39. Millar A.D., Rampton D.S., Chander C.L., Claxson A.W.D., Blake D.R. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease in a rat model of colitis. Gut 1996, 39:407-415.
40. Mitscher L.A., Drake S., Gollapudi S.R., Okwute S.K. A modern look at folkloric use of anti-infective agents. J. Nat. Prod. 1987, 50:1025-1040.
41. Mudeter J., Neurath M.F. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 2007, 13(8):1016-1023.
42. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med 1995, 182:1281-1290.
43. Neurath M.F., Fuss I., Pasparakis M., Alexopouou L., Haralambous S., Meyer zum Buschenfelde K.H., Strober W., Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 1997, 27:1743-1750.
44. Niu X., et al. The anti-inflammatory effects of sanguinarine and its modulation of inflammatory mediators from peritoneal macrophages. Eur. J. Pharmacol. 2012, 689:262-269.
45. Noa M., MD́as R., Carbajal D., ValdD́es S. Effect of D-002 on acetic acid-induced colitis in rats at single and repeated doses. Pharmacol. Res. 2000, 41:391-395.
46. Ogata H., Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr. Pharm. Des. 2003, 9:1107-1113.
47. Packey C.D., Sartor R.B. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J. Int. Med. 2008, 263:597-606.
48. Palmen M.J., Dijkstra C.D., van der Ende M.B., Pena A.S., van Rees E.P. Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats. Clin. Exp. Immunol. 1995, 101:351-356.
49. Parsons L.G., Thomas L.G., Southard G.L., Woodall I.R., Jones B.J.B. Effect of sanguinaria extract on established plaque and gingivitis when supragingivally delivered as a manual rinse or under pressure in an oral irrigator. J. Clin. Periodontol. 1987, 14:381-385.
50. Polgar A., Brozik M., Toth S., Holub M., Hegyi K., Kadar A., et al. Soluble interleukin-6 receptor in plasma and in lymphocyte culture supernatants of healthy individuals and patients with systemic lupus erythematosus and rheumatoid arthritis. Med. Sci. Monit. 2000, 6:13-18.
51. Rachmilewitz D., Simon P.L., Schwartz L.W., Griswald D.E., Fondacaro J.D., Wasserman M.A. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989, 97:326-327.
52. Rachmilewitz D., Karmeli F., Takabayashi K., Hayashi T., Leider-Trejo L., Lee J., Leoni L.M., Raz E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002, 122:1428-1441.
53. Reinisch W., Gasché C., Tillinger W., Wyatt J., Lichtenberger C., Willheim M., Dejaco C., Waldhör T., Bakos S., Vogelsang H., Gangl A., Lochs H. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am. J. Gastroenterol. 1999, 94:2156-2164.
54. Rogler G., Andus T. Cytokines in inflammatory bowel disease. World J. Surg. 1998, 22:382-389.
55. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., et al. Nuclear factor-κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998, 115:537-569.
56. Salim A.S. Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. J. Lab. Clin. Med. 1992, 119:710-717.
57. Sasaki S., Hirata I., Maemura K., Hamamoto N., Murano M., Toshina K., et al. Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the level of mucosal inflammatory cytokines. Scand. J. Immunol. 2000, 51:23-28.
58. Schreiber S., Nikolaus S., Hampe J. Activation of nuclear factor-κB in inflammatory bowel disease. Gut 1998, 42:477-484.
59. Shamma M., Guinaudeau H. Apophinoid alkaloids. Nat. Prod. Rep. 1986, 3:345-351.
60. Stefanelli T., Malesci A., Repici A., Vetrano S., Danese S. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets. Curr. Drug Targets 2008, 9:413-418.
61. Talero E., Sánchez-Fidalgo S., Alarcón de la Lastra C., Illanes M., Calvo J.R., Motilva V. Acute and chronic responses associated with adrenomedullin administration in experimental colitis. Peptides 2008, 29:2001-2012.
62. Tanaka S., Sakata Y., Morimoto K. Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules ICAM-1 and VCAM-1. Planta Med. 2001, 67:108-113.
63. Velayos F.S., Sandborn W.J. Positioning biologic therapy for Crohn's disease and ulcerative colitis. Curr. Gastroenterol. Rep. 2007, 9:521-527.
64. Yamada T., Marshall S., Specian R.D., Grisham M.B. A comparative analysis of two models of colitis in rats. Gastroenterology 1991, 102:1524-1534.
65. Yao J., Wang J.Y., Liu L., Li Y.X., Xun A.Y., Zeng W.S., Jia C.H., Wei X.X., Feng J.L., Zhao L., Wang L.S. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch. Med. Res. 2010, 41:288-294.
66. Yue G., Sun F.F., Dunn C., Yin K., Wong P.Y.K. The 21 aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. J. Pharmacol. Exp. Ther. 1996, 276:265-270.
67. Zhang D.K., Cheng L.N., Huang X.L., Shi W., Xiang J.Y., Gan H.T. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-kappaB activation. Int. J. Colorectal Dis. 2009, 24:5-12.
68. Zhou Y.H., Yu J.P., Liu Y.F., Teng X.J., Ming M., Lv P., An P., Liu S.Q., Yu H.G. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-κBp65, IL-6) in TNBS-induced colitis in rats. Mediat. Inflamm. 2006, 5:92642-92648.